HUM Quote, Financials, Valuation and Earnings

Amedisys has a net margin of 3.87% compared to Humana's net margin of 10.26%. Humana's return on equity of 10.08% beat Amedisys's return on equity of 7.55%.

Humana has a consensus price target of $291.58, signalling upside risk potential of 28.7%. On the other hand Amedisys has an analysts' consensus of $97.38 which suggests that it could fall by -0.11%. Given that Humana has higher upside potential than Amedisys, analysts believe Humana is more attractive than Amedisys.

Humana has a beta of 0.441, which suggesting that the stock is 55.925% less volatile than S&P 500. In comparison Amedisys has a beta of 0.943, suggesting its less volatile than the S&P 500 by 5.651%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.56%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are larger than Amedisys quarterly revenues of $594.8M. Humana's net income of $1.2B is higher than Amedisys's net income of $61M. Notably, Humana's price-to-earnings ratio is 16.02x while Amedisys's PE ratio is 35.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 1.36x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

CVS Health has a net margin of 3.87% compared to Humana's net margin of 1.88%. Humana's return on equity of 10.08% beat CVS Health's return on equity of 7%.

Humana has a consensus price target of $291.58, signalling upside risk potential of 28.7%. On the other hand CVS Health has an analysts' consensus of $79.61 which suggests that it could grow by 24.78%. Given that Humana has higher upside potential than CVS Health, analysts believe Humana is more attractive than CVS Health.

Humana has a beta of 0.441, which suggesting that the stock is 55.925% less volatile than S&P 500. In comparison CVS Health has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.598%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.56%. CVS Health offers a yield of 4.17% to investors and pays a quarterly dividend of $0.67 per share. Humana pays 35.71% of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are smaller than CVS Health quarterly revenues of $94.6B. Humana's net income of $1.2B is lower than CVS Health's net income of $1.8B. Notably, Humana's price-to-earnings ratio is 16.02x while CVS Health's PE ratio is 15.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 0.21x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

HCA Healthcare has a net margin of 3.87% compared to Humana's net margin of 8.79%. Humana's return on equity of 10.08% beat HCA Healthcare's return on equity of 822.75%.

Humana has a consensus price target of $291.58, signalling upside risk potential of 28.7%. On the other hand HCA Healthcare has an analysts' consensus of $390.67 which suggests that it could grow by 7.75%. Given that Humana has higher upside potential than HCA Healthcare, analysts believe Humana is more attractive than HCA Healthcare.

Humana has a beta of 0.441, which suggesting that the stock is 55.925% less volatile than S&P 500. In comparison HCA Healthcare has a beta of 1.473, suggesting its more volatile than the S&P 500 by 47.282%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.56%. HCA Healthcare offers a yield of 0.76% to investors and pays a quarterly dividend of $0.72 per share. Humana pays 35.71% of its earnings as a dividend. HCA Healthcare pays out 11.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are larger than HCA Healthcare quarterly revenues of $18.3B. Humana's net income of $1.2B is lower than HCA Healthcare's net income of $1.6B. Notably, Humana's price-to-earnings ratio is 16.02x while HCA Healthcare's PE ratio is 16.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 1.30x for HCA Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 3.87% compared to Humana's net margin of 3.51%. Humana's return on equity of 10.08% beat Option Care Health's return on equity of 15.22%.

Humana has a consensus price target of $291.58, signalling upside risk potential of 28.7%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 26.89%. Given that Humana has higher upside potential than Option Care Health, analysts believe Humana is more attractive than Option Care Health.

Humana has a beta of 0.441, which suggesting that the stock is 55.925% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.892%.

Humana has a quarterly dividend of $0.89 per share corresponding to a yield of 1.56%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humana pays 35.71% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humana quarterly revenues are $32.1B, which are larger than Option Care Health quarterly revenues of $1.3B. Humana's net income of $1.2B is higher than Option Care Health's net income of $46.7M. Notably, Humana's price-to-earnings ratio is 16.02x while Option Care Health's PE ratio is 24.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humana is 0.23x versus 1.00x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.